Technology 1 hour ago Generative AI Is an Engineering Disaster The Atlantic - By Alex Reisner • 1h A shockingly inefficient trillion-dollar project Editor’s note: This work is part of AI Watchdog, The Atlantic’s ongoing investigation into the generative-AI industry. As they scramble to keep their systems online, AI companies are making things expensive for the rest of us.
Robert Weisman
Boston
As seen in:
MSN,
Boston.com,
Flipboard,
The Boston Globe,
Washington Times,
STAT,
EIN News,
Jewish Boston,
Our Community Now,
Life Science Leader
Staff writer @BostonGlobe and Globe.com. Tracking biotech and the life sciences wave washing over Massachusetts.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Robert Weisman
Mass. (un)vaccination: A new wave of vaccine skepticism threatens readiness for the next pandemic - The Boston Globe
Five years after the COVID outbreak sparked a frantic push for vaccines to build what public health officials called “herd immunity,” a growing number of Americans don’t want to be part of the herd. The rapid COVID vaccines rollout was credited with saving millions of lives. While scientists and health officials hailed it as a triumph of science and logistics, a potent mix of politics, fatigue, and misinformation has taken hold in recent years, leaving much of the public wary.
Snagging ex-Steward hospitals, BrownHealth secures a foothold in Massachusetts
Share Fernandez, 59, in an interview, said he has no specific strategy for Massachusetts, but spoke of a broad patient-centered vision for BrownHealth. “I want patients to leave, after they come to one of our hospitals, [and] say, ‘Wow, what a great experience I had, what great care I got,’” said Fernandez. “If we do that right, then a whole lot of other things fall into place.
With hospital sales set to take effect Monday, Steward’s era in Massachusetts draws to a close
Share “There’s some dislocation that happened,” acknowledged Kate Walsh, the state secretary of health and human services, “but we protected a lot of jobs” at the surviving Steward hospitals. Going forward, she said, “we’ve got the right providers in the right places” to serve patients.
Steward hospitals losing patients as state awaits word on bankruptcy sales
Continue reading More for You
Steward paid nine executives more than $1 million each in year before its bankruptcy filing
Continue reading More for You Continue reading More for You
Patients urge FDA to OK sickle cell therapy
ABSTRACT The treatment, called exa-cel and administered with a single infusion, was as created by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics, which is headquartered in Switzerland but has most of its employees in Mass. BODY Victoria Gray, seen in 2019, said that after receiving the treatment she no longer had pain. A microscope photo showed crescent-shaped red blood cells from a patient with sickle cell disease.
Boston Globe: No more outsourcing? Making drugs locally is a key focus of the life sciences industry.
The following excerpts are from a story by Robert Weisman originally published to BostonGlobe.com on July 13, 2023. State officials are also mindful of the need to extend the industry’s footprint throughout Massachusetts as it steps out of its hub in Cambridge’s Kendall Square to sites in Watertown, Somerville, Boston’s Fenway neighborhood, and beyond. Middlesex County, home to Cambridge, accounts for nearly half of the state’s biomanufacturing jobs.
The Netherlands makes aging and long-term care a priority. In the US, it’s a different story.
THE HAGUE Ademographic tidal wave looms. By 2040, one in four Dutch residents will be over 65. The same “silver tsunami’’ is building in much of the developed world, including the United States. And it will strain the budgets and test the ingenuity of nations. Here in the Netherlands, a social welfare state roughly twice the size of Massachusetts, leaders have been planning for this graying of society for a half-century.
Massachusetts lagging most other states in COVID-19 vaccination rollout
© Lane Turner/Globe Staff Gene Leonard, a WWII Army Air Corps gunner who served on a B-17 in Europe, beamed after getting his vaccine from Walgreens pharmacists Erin Smith at the Brightview Country Club Heights in Woburn. Six weeks after the first COVID-19 vaccines were authorized for emergency use, Massachusetts — celebrated as a national health care leader — ranks in the bottom half of US states in getting injections into the arms of its residents.
Costs of long-term care stagger states
It’s the late-in-life financial hit that can wipe out your savings and your children’s inheritance. Yet few in middle age want to think about, or prepare for, a time when they’ll need “long-term care’’ — help with walking, dressing, or going to the bathroom. The cost of such care is growing as the population ages, straining family finances and Medicaid budgets. Holding out little hope that a gridlocked Congress will come to the rescue, states are jumping into the breach.
Housing crunch awaits aging boomers
MARLBOROUGH — As snow melted outside the columned entrance to the Christopher Heights assisted living complex last week, Mary Massauro celebrated her 101st birthday with lobster pot pie, a blue balloon tied to her chair. Residents chatted in the dining room about family and politics. Down the hall, 92-year-old Dottie Creamer was enjoying a visit with her son.
Drug maker scrambling to boost supply of new shingles vaccine as many in Mass. wait
© Jonathan Wiggs /Globe Staff Ann Deluty has received only one of her two vaccine shots for shingles. Susan Grosdov’s doctor recommended in August that she get a shot of Shingrix — a powerful new vaccine that can prevent the pain, rashes, and general misery of shingles. The only problem? There was none in stock. So Grosdov, 66, a retired Harvard Medical School administrator, returned in November, but the vaccine was still unavailable.
Older execs turn gurus to boost nonprofit missions
Martha Sloan Felch grew up in comfortable suburbs of Philadelphia and Chicago. She earned an MBA before launching a successful banking career, with tours at Shawmut, Fleet, and smaller Massachusetts banks. But on a recent weekday, Felch found herself in a borrowed conference room, trying to guide a fledgling nonprofit through a leadership transition.
Help wanted, but not from older workers: Many struggle to find jobs as employers post openings
It’s late afternoon at the Venture Café in Cambridge’s Kendall Square. The tables are teeming with techies in T-shirts, sipping beer and pecking on laptops. Everybody works for a start-up, every start-up is hiring — now or soon —and every new hire seems younger than the last. “I’m feeling old,” jokes Xhulia Bratja, a manager at a fledgling data analytics firm, who turns 25 this week. Eight miles north, Justin O’Connor, 65, pours coffee for customers at the cozy Fuller Cup in Winchester.
Baby boomers destroyed their hearing. Biotech is trying to fix it
Baby boomers grew up with music blasting from dorm room turntables, car stereos, and arenas where the sound of a band at full throttle could rival the roar of a jet engine. Volume became an act of generational defiance. As rocker Ted Nugent put it: “If it’s too loud, you’re too old.” Turns out, it was too loud.
Baby Boomers' failing ears drive search for a cure for hearing loss
Baby boomers grew up with music blasting from dorm room turntables, car stereos, and arenas where the sound of a band at full throttle could rival the roar of a jet engine. Volume became an act of generational defiance. As rocker Ted Nugent put it: “If it’s too loud, you’re too old.” Turns out, it was too loud.
Baby boomers destroyed their hearing. Biotech is trying to fix it
Baby boomers grew up with music blasting from dorm room turntables, car stereos, and arenas where the sound of a band at full throttle could rival the roar of a jet engine. Volume became an act of generational defiance. As rocker Ted Nugent put it: “If it’s too loud, you’re too old.” Turns out, it was too loud.
Baby boomers destroyed their hearing. Biotech is trying to fix it
Baby boomers grew up with music blasting from dorm room turntables, car stereos, and arenas where the sound of a band at full throttle could rival the roar of a jet engine. Volume became an act of generational defiance. As rocker Ted Nugent put it: “If it’s too loud, you’re too old.” Turns out, it was too loud.
Baby boomers destroyed their hearing. Biotech is trying to fix it
Baby boomers grew up with music blasting from dorm room turntables, car stereos, and arenas where the sound of a band at full throttle could rival the roar of a jet engine. Volume became an act of generational defiance. As rocker Ted Nugent put it: “If it’s too loud, you’re too old.” Turns out, it was too loud.
Balancing Biopharma's Bright Future Against Its Tarnished Image — Insights From 6 Retired CEOs
By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Francois Nader knows of dark days. “When I joined NPS [Pharmaceuticals] we downsized the company from 450 people to 17,” he says. The company’s former CEO admits that was one of his most hated days as an executive, and he vowed never to put either himself or the company in a situation where he’d have to do that again.
How Genzyme became a big source of biotech executives
CAMBRIDGE, Mass. (AP) - They command battalions of biotechnology workers from Kendall Square to Seattle to Stockholm. They lean on each other for business advice while poaching one another’s researchers. And they share a pedigree that is pure gold in the life sciences world.
Broad Institute, Google Genomics to develop online tools to analyze genetic data
The Broad Institute of MIT and Harvard, which has amassed the world’s largest collection of genetic data about diseases, is teaming up with Google to create a simpler way to help far-flung scientists pursue their own research online.
Traffic congestion, choke points bedevil innovators in Kendall Square
DAVID L. RYAN/GLOBE STAFF The whiz kids of Kendall Square helped build the Internet and sequence the human genome. Now they’re turning their attention to what may be a more formidable challenge: figuring out how to get to work. Over the last five years, companies have occupied more than 1.6 million square feet of new office and lab space while adding more than 5,000 jobs, according to the Cambridge Redevelopment Authority and the Kendall Square Association.
Seven things you should know about Amy Schulman
Amy Schulman, who recently left her job as general counsel at Pfizer Inc. in New York, began work this week at Boston venture capital firm Polaris Partners. The firm’s first female venture partner, Schulman, 53, will work with early-stage companies in health care and life sciences. She also will serve as chief executive of a Polaris-backed startup, Arsia Therapeutics. Globe reporter Robert Weisman talked with Schulman last week outside Arsia’s lab at the Lab Central incubator in Cambridge.
Many local biotech stocks among those hit hard by this week’s sharp selloff in financial markets
Long-galloping biotechnology shares stumbled this week, falling harder than the broader financial markets as stock watchers cited a move away from riskier investments. As stock prices plummeted, four US biotech startups, including Aldeyra Therapeutics of Burlington, delayed initial public offerings planned for late this week.
FDA chief calls for a ‘new era of partnership’ with biotech firms at conference
CAMBRIDGE — The head of the US regulatory agency that approves medicines Friday called for “a new era of partnership” with the biopharmaceutical industry in bringing new treatments to patients. “We see this model emerging where we don’t just wait for an application to come to us,” Food and Drug Administration commissioner Margaret Hamburg told more than 300 drugmaking executives at the annual meeting of the Massachusetts Biotechnology Council trade group.
Biogen Idec chief warns drug development could be hurt by cuts in funding and reimbursments
CAMBRIDGE — The top executive of Biogen Idec Inc. said Thursday that the state’s drug makers are producing breakthrough treatments for conditions ranging from multiple sclerosis to hepatitis C to hemophilia. But he warned future innovation is threatened by federal funding cuts for basic research and payments that don’t allow companies to recover their investments.
Tetraphase Pharmaceuticals wins FDA’s fast-track status to develop urinary tract infection treatment
Tetraphase Pharmaceuticals Inc., a Watertown biotech that helped ignite a wave of initial public offerings when it went public a year ago, Wednesday said it has won fast-track designation from the Food and Drug Administration to develop an antibiotic to treat urinary tract infection. The fast-track status is awarded to speed up the study and regulatory review of drugs that fight serious or life-threatening conditions.
New collaboration deal gives Celgene option to acquire Forma Therapeutics of Watertown
One year after it struck an agreement to collaborate with New Jersey-based Celgene Corp. to make drugs that regulate the level of proteins in cells, Forma Therapeutics of Watertown said it has reached a second deal to work with Celgene across a range of therapeutic areas. The new deal gives Celgene an exclusive option to acquire Forma at some time in the future. Under the second deal, Forma retains the rights to define its own research strategy and select drug targets.
FDA advisory panel recommends approval of Cubist treatment for bacterial skin infections
An influential advisory panel Monday recommended that the Food and Drug Administration approve a new Cubist Pharmaceuticals Inc. drug to treat acute bacterial skin infections, sending the Lexington drug maker’s application to the FDA for a ruling later this spring.
US approves Biogen Idec treatment for one type of hemophilia
Federal regulators Friday approved a long-acting Biogen Idec drug as the first new hemophilia treatment in 17 years, launching a new class of therapies to control and prevent bleeding in people with hemophilia and opening a potentially lucrative new market for Biogen Idec, the largest biotechnology company in Massachusetts. The drug, called Alprolix, was okayed by the US Food and Drug Administration specifically for adults and children with hemophilia B, one type of the disease.
Kendall needs to take on harder challenges says Eric Lander
Calling the Boston area the center of the global revolution in biology and Kendall Square “the center of the center,” Eric Lander, president of the Broad Institute of MIT and Harvard, this morning called on innovators in the square to take on harder scientific and technology challenges. “If you’re not working on something that sounds nuts, what’s the point?” Lander asked his audience of more 150 people at the annual meeting of the Kendall Square Association at the Boston Marriott Cambridge.
Biogen Idec receives Canadian regulator approval for Alprolix
Biogen Idec Inc. this morning said it had received approval from Canadian regulators to sell a new drug to control and prevent bleeding and routine prophylaxix in adults and children over 12 years old with hemophilia B. The drug, called Alprolix, is the most far-reaching advance in hemophilia B therapies in nearly two decades and marks the first treatment beyond multiple sclerosis in Cambridge-based Biogen Idec’s portfolio.
Akebia Therapeutics shares climb 57 percent after IPO
Shares of Akebia Therapeutics Inc. surged more than 57 percent in their market debut Thursday after the Cambridge startup raised $100 million in an initial public offering. Akebia, which is developing drugs to treat patients with chronic kidney disease, sold 5.8 million shares of common stock at $17 a share lateWednesday in the seventh initial public offering this year by a Massachusetts-based biopharmaceutical company. The company’s shares advanced $9.70 to close at $26.70 on the Nasdaq exchange.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Robert
Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack